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he Role of C-Reactive Protein
ctivation of Nuclear Factor
appa-B in the Pathogenesis
f Unstable Angina*
shwarlal Jialal, MD, PHD, Sridevi Devaraj, PHD
acramento, California
nflammation is pivotal in all phases of atherosclerosis, from
he nascent lesion to the culmination in acute coronary
yndromes (ACS) (1). Nuclear factor kappa-B (NF-B) is a
aster switch in the inflammatory cascade and indeed has
een documented in human atheroma (2). C-reactive pro-
ein (CRP), the prototypic marker of inflammation, has
een advanced as a risk marker for heart disease, and indeed
n patients with unstable angina higher levels augur a poorer
rognosis (3). Whether CRP definitely participates in this
rocess remains to be proven. In this issue of the Journal,
iuzzo et al. (4) carefully document that patients with
nstable angina with elevated levels of CRP (3 mg/l) have
ncreased monocytic NF-B activity and increased release of
roinflammatory cytokines, interleukin (IL)-6, and tumor
ecrosis factor (TNF) from lipopolysaccharide (LPS)-
timulated monocytes. Furthermore, they show, in an albeit
imited sample size, that the patients with unstable angina
ith elevated CRP and increased NF-B activity have the
orst outcomes based on recurrence of acute coronary
vents. Therefore, they argue that CRP might indeed be a
articipant in the genesis and clinical sequelae of ACS.
See page 185
Nuclear factor kappa-B is a pivotal transcription factor
nd the promoter of most of the critical proinflammatory
ytokines, chemokines, and so on, which have NF-B
inding sites. Also, NF-B has been documented in human
theroma, and it has recently been suggested that NF-B
ay be critical in plaque instability by transducing patho-
enic stimulation of genes that promote recruitment and
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Laboratory for Atherosclerosis and Metabolic Research, University ofm
alifornia at Davis Medical Center, Sacramento, California. Supported by National
nstitutes of Health grants R01 HL074360 and K24 AT00596.ctivation of cells pivotal in coronary plaques. Activation of
F-B has been identified in monocyte macrophages,
mooth muscle cells (SMC), and endothelial cells (EC) in
uman atherosclerotic vessels but not in healthy vessels.
urthermore, plaques from patients with ACS exhibit
ncreased expression of several NF-B–regulated genes such
s cytokines, chemokines, and so on.
The important question that arises is whether CRP
ctivates NF-B, as suggested by Liuzzo et al. (4), and if
his has effects on vascular cells that are relevant to athero-
hrombosis and ACS. Indeed, although Liuzzo et al. (4)
how increased NF-B activation with carefully purified
RP on human monocytes, it is important to emphasize
hat this has also been documented in vascular smooth
uscle cell (VSMC) and EC. However, the first demon-
tration that CRP activation of NF-B induces a relevant
roinflammatory effect was the observation by Devaraj et al.
5), who clearly showed that CRP induced expression of the
ritical chemokine IL-8, a powerful trigger of monocyte
dhesion to endothelium in human aortic (HA) EC and
uman coronary artery (HCA) EC via up-regulation of
F-B, using 3 different techniques: electrophoresis mo-
ility shift assay, nuclear p65, and IB kinase in the cytosol.
hose investigators also showed, using various inhibitors of
F-B, that the effect of CRP on IL-8 could be abrogated.
Another important effect of purified CRP that is perti-
ent to the paper of Liuzzo et al. (4) is the demonstration of
ncreased plasminogen activator inhibitor 1 (PAI-1) activity
n aortic endothelial cells since PAI-1 impairs fibrinolysis.
akakuki et al. (6) carefully documented that the activation
f PAI-1 by purified CRP is through Rho kinase signaling
athway via activation of NF-B. Using various strategies,
ncluding inhibitors, they carefully showed that inhibiting
ho inhibited NF-B and PAI-1.
Further relevance of CRP activation of NF-B was recently
eported by 3 independent laboratories with respect to mono-
yte endothelial cell adhesion (7–9). Kawanami et al. (7)
emonstrated in bovine EC that CRP induced vascular cell
dhesion molecule (VCAM) 1 expression through the NF-B
ignaling pathway. In addition, they suggest that the p65
omodimer but not the p65/p50 heterodimer binds to NF-
B–binding sites of the VCAMpromoter, suggesting that p65
omodimer and not p65/p50 heterodimer is an important
ransactivator in CRP-stimulated VCAM gene expression in
ascular EC. It would have been important to demonstrate that
his indeed was relevant to monocyte adhesion to EC. How-
ver, 2 subsequent papers examined the effect of CRP on
onocyte adhesion. In the paper by Liang et al. (8), they show
hat CRP induces VCAM expression in human venous EC
nd this results in increased monocyte adhesion to EC.
reviously, Devaraj et al. (9) delineated that purified CRP
ugments monocyte-EC adhesion under static conditions via
he Fc receptors CD32 and CD64. In the paper by Liang et al.
8), they showed that CRP activates NF-B in EC. Further-
ore, they showed that by blocking CD32 using siRNA, they
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Editorial Comment January 16, 2007:195–7revent VCAMup-regulation by CRP. They also showed that
RP induces IB degradation and nuclear translocation of
F-B in human umbilical vein and HAEC and that this was
nhibited by CD32. These studies were done mainly in venous
C, and they did not report on the role of CD64 in
RP-induced activation of NF-B and adhesion.
In a continuation of their previous findings, Devaraj et al.
9) showed that in HAEC purified CRP induces intercel-
ular adhesion molecule (ICAM), VCAM, NF-B, and
onocyte EC adhesion under static conditions. Using
nhibitors and a dominant negative to IB, they demon-
trated significantly decreased ICAM, VCAM, and subse-
uent monocyte-EC adhesion. Finally, by preincubating
ith antibodies to CD32 and CD64 and using transient
ransfection of CD32 siRNA, they attenuated CRP-induced
F-B activity, ICAM, VCAM, and monocyte-EC adhe-
ion. Furthermore, they showed that by blocking CD32 and
D64, they prevented purified CRP-activated EC-supported
onocyte rolling, transmigration, and adhesion under shear
ow (2 dynes/cm2).
Thus, collectively these 3 groups have independently
rrived at a similar conclusion, i.e., monocyte EC adhesion
nd CAM up-regulation is mediated via NF-B activation
y CRP. The latter 2 groups went further and showed that
his was largely through the Fc receptor.
Also, Hattori et al. (10) have shown that monocyte che-
oattractant protein-1 (MCP-1) stimulation by CRP in
SMC is probably mediated via NF-B, and Cirillo et al. (11)
uggest that CRP induces tissue factor expression in EC and
SMC via NF-B. However, those authors did not use
ominant negative or other state-of-the-art inhibitors of
F-B.
To summarize, the effects of CRP that can be ascribed to
F-B activation include up-regulation of IL-8, MCP-1,
nd PAI-1, and increased ICAM, VCAM, monocyte-EC
dhesion, and tissue factor (Table 1). Although these effects
re important in atherogenesis, they clearly could contribute
o the genesis of ACS by recruiting leukocytes and promot-
ng thrombosis.
Thus, these in vitro findings concur with the observation
iologic Effects Mediatedhrough CRP Activat on of NF-B
Table 1 Biologic Effects MediatedThrough CRP Activation of NF-B
IL-8 Chemokine that promotes neutrophil and monocyte
EC adhesion
MCP-1 Chemokine that promotes monocyte chemotaxis
and recruitment
PAI-1 Key regulator of fibrinolysis by inhibiting tissue
plasminogen activator
ICAM-1, VCAM-1 Soluble cell adhesion molecules that activate
monocyte adhesion to endothelium
Tissue factor Primary initiator of the serine protease cascade of
the coagulation system promoting thrombosis
C  endothelial cell; ICAM  intercellular adhesion molecule; IL  interleukin; MCP monocyte
hemoattractant protein; NF-B  nuclear factor kappa-B; PAI  plasminogen activator inhibitor;
CAM  vascular cell adhesion molecule.f Liuzzo et al. (4) that in monocytes CRP also activatesF-B. Disappointingly, Luizzo et al. did not explore if
his activation of NF-B resulted in the induction of IL-6
nd TNF in unstable angina patients with elevated CRP
evels. Liuzzo et al. (4) also found that patients with
ncreased CRP and activated NF-B in monocytes had at
east a 2-fold greater frequency of acute coronary events.
owever, the sample size was small, and this important
bservation needs to be confirmed in larger clinical trials.
lthough the investigators do not report on statin use per se
n the study population, it is important to point out that in
ddition to statins as a class of drugs lowering CRP (12),
hey may also have effects in ameliorating proinflammatory
nd prothrombotic effects of CRP on EC (13). In this
egard, it is germane to point out the in the PROVE-IT
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py) study (14) the concomitant reduction of low-density
ipoproteins and CRP resulted in greatest benefit.
Finally it should be borne in mind that the relationship
etween CRP and NF-B could be bidirectional. In
ddition to CRP mediating proinflammatory effects as
utlined above, CRP mRNA and protein has been
ocumented in human atheroma and vascular cells by
any investigators (15). Interestingly, in carotid ather-
ma CRP appears to colocalize with NF-B (16). Also,
n hepatocytes regulation of CRP is under transcriptional
ontrol of NF-B, STAT3, and CEBP (17). Thus, it is
ot unreasonable to presuppose that upon activation,
ascular cells in atheroma could also be producing CRP
y activation of NF-B, which could further induce a
icious cycle culminating in ACS (18).
eprint requests and correspondence: Dr. Ishwarlal Jialal,
athology/Medicine, UC Davis Medical Center, 4635 Second
venue, Sacramento, California 95817. E-mail: ishwarlal.jialal@
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